AKT1 and neoplasm: Importantly, apart from steric hindrance to anti-HER2 antibody binding through ECM components in tumor, we found a potential mechanism related to trastuzumab resistance that ECM could activate PI3K-AKT signaling pathway and inhibit the subsequent apoptosis signaling, thus impairing the anti-tumor effect of trastuzumab.